Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells $139,500.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $45.00, for a total transaction of $139,500.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,901,070. The trade was a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.88, for a total transaction of $142,228.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total value of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total value of $154,318.00.

RxSight Stock Up 0.7 %

RXST stock opened at $46.40 on Friday. RxSight, Inc. has a 12 month low of $28.88 and a 12 month high of $66.54. The firm’s 50-day moving average is $48.85 and its 200 day moving average is $52.44.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RXST. Wells Fargo & Company lowered their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Finally, Jefferies Financial Group initiated coverage on shares of RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $61.63.

Hedge Funds Weigh In On RxSight

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of RxSight by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after acquiring an additional 40,500 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in RxSight by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 60,908 shares of the company’s stock worth $3,143,000 after purchasing an additional 994 shares during the period. California State Teachers Retirement System raised its position in RxSight by 6.8% during the 1st quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock valued at $1,395,000 after purchasing an additional 1,733 shares in the last quarter. RA Capital Management L.P. lifted its holdings in shares of RxSight by 1.1% in the 1st quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock worth $177,581,000 after buying an additional 38,540 shares during the period. Finally, CWM LLC grew its position in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.